Design and synthesis of 3-benzylaminocoumarin-7-O-sulfamate derivatives as steroid sulfatase inhibitors.

Compounds 3j inhibited human placenta steroid sulfatse with IC 50 of 0.13 μM and displayed ireversible kinetic of K I 0.08 μM and K in cat 158 min−1. • Nineteen 3-aminocoumarin-7- O -sulfamates were designed and synthesized. • SAR revealed that modification at 3-position of coumarin resulted in enhancing STS inhibition. • Substitution at benzyl of 3-benzyl-aminocoumarin-7- O -sulfamates was crucial for STS inhibition. • Compound 3j inhibited STS from human placenta (IC 50 130 nM) and MCF-7 (IC 50 1.35 µM). Steroid sulfatase (STS) is a sulfatase enzyme that catalyzes the conversion of sulfated steroid precursors to free steroid. The inhibition of STS could abate estrogenic steroids that stimulate the proliferation and development of breast cancer, and therefore STS is a potential target for adjuvant endocrine therapy. In this study, a series of 3-benzylaminocoumarin-7- O -sulfamate derivatives targeting STS were designed and synthesized. Structure-relationship activities (SAR) analysis revealed that attachment of a benzylamino group at the 3-position of coumarin improved inhibitory activity. Compound 3j was found to have the highest inhibition activity against human placenta isolated STS (IC 50 0.13 μM) and MCF-7 cell lines (IC 50 1.35 µM). Kinetic studies found compound 3j to be an irreversible inhibitor of STS, with K I and k inact value of 86.9 nM and 158.7 min−1, respectively. [ABSTRACT FROM AUTHOR]